Dietary supplementation with partially hydrolyzed guar gum helps improve constipation and gut dysbiosis symptoms and behavioral irritability in children with autism spectrum disorder

Ryo Inoue,1,2* Yuko Sakaue,2 Yuki Kawada,1 Ryuji Tamaki,1 Zenta Yasukawa,1 Makoto Ozeki,3 Satoko Ueba,4 Chihiro Sawai,2 Kazuo Nonomura,4 Takamitsu Tsukahara5 and Yuji Naito6

1Laboratory of Animal Science, Department of Agriculture and Life Science, Kyoto Prefectural University, 1-5 Shimogamohangi-cho, Sakyo-ku, Kyoto 606-8522, Japan
2Department of Pediatrics, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan
3Taiyo Kagaku Co., Ltd., 1-3 Takaramachi, Yokkaichi, Mie 510-0844, Japan
4Moriyama Municipal Hospital, 4-14-1 Moriyama, Shiga 524-0022, Japan
5Kyoto Institute of Nutrition & Pathology, Ujitawara, Kyoto 610-0231, Japan
6Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan

Prebiotic dietary water-soluble fiber obtained from partially hydrolyzed guar gum was added to diets of children with autism spectrum disorders who presented constipation symptoms. Supplementation with partially hydrolyzed guar gum altered gut microbiota and significantly increased the frequency of defecation per week and altered the gut microbiota. In addition, supplementation with partially hydrolyzed guar gum significantly (p<0.05) decreased and tended to decrease (p = 0.07) the concentrations of serum interleukin-1β and tumor necrosis factor-α, respectively. More importantly, supplementation with partially hydrolyzed guar gum significantly ameliorated behavioral irritability as per the Aberrant Behavior Checklist, Japanese Version. The present study demonstrated that supplementation with partially hydrolyzed guar gum to diets of constipated autism spectrum disorders children helped improve constipation and gut dysbiosis symptoms, which in turn helped attenuate the level of serum inflammation cytokines and behavioral irritability.

Key Words: gut microbiota, autism spectrum disorders, dietary fiber, constipation

Growing evidence has shown that children with autism spectrum disorders (ASD) present abnormal composition of the gut microbiota, a condition also known as gut dysbiosis.1) Gut dysbiosis putatively leads to systemic inflammation and neuro-inflammation of the central nervous system that ultimately impairs brain functions (Gut-Brain Axis).2) Previously, we reported that in the fecal microbiota of Japanese ASD children, the abundance of bacterial genera Faecalibacterium and Blautia strongly correlated with the expression level of inflammatory genes in peripheral mononuclear blood cells (PBMCs). Moreover, the abundance of these two bacterial genera in Japanese ASD children was significantly different from that in typically developed (TD) children used as control.3) In addition, modulation of the gut microbiota via probiotic supplementation and diet intervention seems to help treat ASD effectively, as reviewed by Li et al.4) Thus, existing evidence strongly suggests that gut dysbiosis may be at least partially involved in the etiology of ASD and could be a potential therapeutic target.

Constipation is currently believed to be a causative factor of gut dysbiosis.4,5) Furthermore, constipation is known to be one of the major gastrointestinal disorders observed in children with ASD.5) For example, Ibrahim et al.6) found an incidence of constipation in 33.9% of 124 ASD children, which was significantly higher than that found in TD children used as control. Thus, the presence of constipation symptoms should be included as a critical factor when developing a treatment for ASD children.

Partially hydrolyzed guar gum (PHGG) is defined as a form of prebiotic dietary water-soluble fiber whose supplementation reportedly modulates the gut microbiota in healthy adults.7,8) More importantly, PHGG can be added without affecting the appearance or the flavor of diets and hence it is easy to give even to ASD children with exaggerated food preferences.

To the best of our knowledge, only one study has evaluated the effect of prebiotics on ASD children.9) Although Grimaldi et al.9) elegantly demonstrated that prebiotic galacto-oligosaccharides (GOS) altered the composition of gut microbiota in ASD children, anti-social behavior only improved when GOS supplementation was paired with food intervention.

In the present study, we aimed to evaluate the effect of prebiotic PHGG supplementation with no food intervention on constipation and gut dysbiosis symptoms and behavioral irritability in ASD children. To select ASD children as donors for the experiment, we set the presence of constipation symptoms as the critical criterion.

Materials and Methods

Ethical statement. The present study was registered in the UMIN Clinical Trial Registry (UMIN000034625) and conducted according to the Declaration of Helsinki. All procedures were approved by the Institutional Review Board of Shiga University of Medical Science (Approval Number: 27-161). Due to the limited comprehension of ASD children who acted as donors, written consent was obtained from all guardians.

*To whom correspondence should be addressed.
E-mail: r.inoue@kpu.ac.jp

©2019 JCBN

doi: 10.3164/jcbn.18-105
Original Article
J. Clin. Biochem. Nutr. | May 2019 | vol. 64 | no. 3 | 217–223
informed consent was obtained from their parents. Therefore, ASD children were unaware of PHGG supplementation. The privacy rights of ASD children were observed at all times.

**Subjects and study protocol.** Thirteen outpatient children with ASD in the range of 4–9 years of age and living in similar geographic regions in Japan were enrolled in the present study (Table 1). The children were pre-categorized by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria(10) and then diagnosed according to the Pervasive Developmental Disorders Autism Society Japan Rating Scale (PARS)(11) and Modified Check-list for Autism in Toddlers (M-HAT). No medication (e.g., drugs or antibiotics) was administered to any of the children to treat either constipation or ASD for at least one month prior to the sampling period.

In the present study, none of the children underwent food intervention, but all of them were given PHGG supplementation (6 g/day; Taiyo Kagaku Co. Ltd., Mie, Japan). For easy ingestion, PHGG was dissolved in either food or a drink and given to ASD children during the period of regular examinations in the hospital, which lasted two months or longer (Table 1). The commercial PHGG concoction used in the present work was obtained from Taiyo Kagaku Co. Ltd. (Sunfiber; Yokkaichi, Japan). The PHGG concoction was prepared by treating guar gum with β-endogalactomannase produced by a strain of Aspergillus niger.

Parents of the 13 ASD children recorded their frequency of defecation weekly, from the week prior to the start of PHGG supplementation to the week prior to the end of PHGG supplementation. Moreover, feces were collected twice by the parents: one month prior to the sampling period and twice weekly in the remaining four ASD children prior to PHGG supplementation.

**Collection of feces and serum.** Freshly evacuated feces were collected pre- and post-supplementation of PHGG using a stool collection brush and a storage tube (Wako Pure Chemicals, Osaka, Japan), which contained a DMSO-EDTA-salt solution (DESS) for the preservation of bacterial DNA. Peripheral blood was drawn pre- and post-supplementation of PHGG from nine of the children and collected in Venoject II vacuum blood collection tubes (serum collection tubes) (Terumo Medical Corp., Tokyo, Japan). Serum was collected by centrifuging the blood samples at 1,400 × g, room temperature for 10 min.

**Analysis of fecal microbiota by 16S rRNA metagenomics.**

| Variable                              | Pre-PHGG supplementation | Post-PHGG supplementation |
|---------------------------------------|---------------------------|---------------------------|
| Total N (male/female)                 | 13 (12/1)                 |                           |
| N for feces and serum (male/female)   | 8 (7/1)                   |                           |
| N for only feces (male/female)        | 4 (4/0)                   |                           |
| N for only serum (male/female)        | 1 (1/0)                   |                           |
| Age (years)                           | 5.9 ± 2.2                 |                           |
| Defecation frequency (weeks)          | 1.3 ± 0.5                 | 2.8 ± 0.7*                |
| ABC irritability subscale             | 15.1 ± 3.3                | 11.8 ± 1.9*               |
| Period of PHGG ingestion (months)     | 2–15 (median = 2)         |                           |

**Table 1. Profiles of enrolled ASD children**

| Variable                              | Pre-PHGG supplementation | Post-PHGG supplementation |
|---------------------------------------|---------------------------|---------------------------|
| Total N (male/female)                 | 13 (12/1)                 |                           |
| N for feces and serum (male/female)   | 8 (7/1)                   |                           |
| N for only feces (male/female)        | 4 (4/0)                   |                           |
| N for only serum (male/female)        | 1 (1/0)                   |                           |
| Age (years)                           | 5.9 ± 2.2                 |                           |
| Defecation frequency (weeks)          | 1.3 ± 0.5                 | 2.8 ± 0.7*                |
| ABC irritability subscale             | 15.1 ± 3.3                | 11.8 ± 1.9*               |
| Period of PHGG ingestion (months)     | 2–15 (median = 2)         |                           |

Defecation frequency and ABC irritability subscales were recorded from all participating ASD children. *p<0.01.

Quantification of serum cytokine and chemokine concentrations. The concentrations in serum of cytokines IFN-α, IL-1β, IL-6, IL-10, IL-12p70 and TNF-α and chemokines IF-10, I-TAC and MIG were simultaneously measured by a cytometric bead array (CBA; BD, Tokyo, Japan) using a flow cytometer (Accuri C6; BD). All procedures for quantitation were conducted as per the manufacturers’ instructions.

**Statistical analysis.** α-Diversity indices Chaol (richness) and Shannon (evenness) were calculated with the R phyloseq package. β-Diversity was estimated based on Bray-Curtis distances and tested by a principal coordinate analysis (PCoA) using phyloseq. The Bray-Curtis distance between the samples was statistically analyzed by a permutational multivariate analysis of variance (PERMANOVA). α-Diversity indices, the relative abundance (%) of bacterial genera, OTUs (operational taxonomic units) in the fecal microbiota, and the concentrations of cytokines and chemokines in pre- and post-PHGG supplementation samples were statistically compared using a paired Wilcoxon signed-rank test. Correlations between the frequency of defecation or the ABC-I irritability subscales and the relative OTU abundance were assessed by the Spearman’s rank correlation test using R software. Statistical significance was considered at p<0.05.

**Results**

Frequency of defecation and ABC-J scoring. Defecation was observed only once per week in nine of the 13 ASD children and twice weekly in the remaining four ASD children prior to PHGG supplementation. During a week prior to the end of PHGG, it was observed that defecation increased from two times to four times per week in all children (Table 1; p<0.01). Significant differences were detected between pre- and post-PHGG supplementation per the ABC-J irritability subscales. Indeed, the ABC-J irritability subscale was 15.1 ± 3.3 prior to PHGG supplementation, but decreased to 11.9 ± 1.9 after supplementing PHGG (Table 1; p<0.01). Nonetheless, other subscales of ABC-I remained unchanged despite PHGG supplementation (data not shown).

**Gut microbiota.** α-Diversity, both Chaol and Shannon indices significantly decreased by PHGG supplementation (Fig. 1; p<0.05). The coordinates in the PCoA plots changed from pre- to post-PHGG supplementation for most PHGG-supplemented children, but β-diversity did not significantly differ between the data from the pre- and post-PHGG supplementation periods due to wide individual differences in the coordinates of PCoA prior to PHGG supplementation (Fig. 2). The relative abundance of nine bacterial genera changed significantly upon PHGG supplementation (Fig. 3). For example, the relative abundance of genera Blautia and Acidaminococcus increased significantly and that of genera Streptococcus, Odoribacter and Eubacterium (belonging to the family Erysipelotrichaceae) decreased significantly upon

**Table 1. Profiles of enrolled ASD children**

- **Variable**: Total N (male/female), N for feces and serum (male/female), N for only feces (male/female), N for only serum (male/female), Age (years), Defecation frequency (weeks), ABC irritability subscale, Period of PHGG ingestion (months).
- **Pre-PHGG supplementation**: 13 (12/1), 8 (7/1), 4 (4/0), 1 (1/0), 5.9 ± 2.2, 1.3 ± 0.5, 15.1 ± 3.3, 2–15 (median = 2).
- **Post-PHGG supplementation**: 2.8 ± 0.7*, 11.8 ± 1.9*.

*p<0.01.

©2019 JCBN

doi: 10.3164/jcbn.18-105
PHGG supplementation. However, four of nine genera significantly affected by PHGG supplementation were unclassified genera. As a result, it was decided to statistically compare the relative abundance of OTUs. PHGG supplementation significantly changed the relative abundance of 19 OTUs (Table 2). For example, PHGG supplementation significantly increased OTU_7, OTU_9 and OTU_52, which showed a high homology to *Fusocatenibacter saccharivorans*, *Blautia wexlerae* and *Acidaminococcus intestini*, respectively, but it significantly decreased 16 OTUs including OTU_68 showing a high homology to *Bacteroides ovatus*.

**Serum cytokines and chemokines.** PHGG supplementation significantly decreased IL-1β (*p* < 0.05) and tended to decrease IL-6 (*p* = 0.05) and TNF-α (*p* = 0.07), but did not affect other cytokines and chemokines (Fig. 4).

**Correlation of the OTU abundance with frequency of defecation and ABC-J irritability subscale.** While the relative abundance of OTU_9 showed a significant positive correlation with the frequency of defecation, the relative abundance of OTU_75 and OTU_146 correlated negatively with the frequency of defecation (*p* < 0.05; Table 2 and Fig. 5). Finally, OTUs; OTU_41, OTU_53, OTU_68 and OTU_117 showed a significant positive correlation with the ABC-J irritability subscales (*p* < 0.05; Table 2 and Fig. 5).
Discussion

Recently, a greater number of ASD cases have been reported worldwide. According to a study by Idring et al. in Sweden, the prevalence of ASD in children aged 2–17 increased almost 3.5-fold from 2001 to 2011. The gut microbiota is one of the environmental factors involved in the ASD etiology and consequently, is attracting attention as a potential new therapeutic target. In the present study, we aimed to evaluate the effect of prebiotic PHGG supplementation with no food intervention on constipated ASD children.

Constipation symptoms in ASD children markedly improved Fig. 3. Comparative analysis of the taxonomic composition of the fecal microbiota at the genus level. Bacterial genera with significant differences between pre- and post-supplementation of PHGG are presented.

| OTU_ID | Nearest known bacterial species (BLANSTn) | Accession No. | Homology | Abundance (%) | Correlation with defecation frequency | Correlation with ABC irritability subscale |
|--------|------------------------------------------|---------------|----------|---------------|----------------------------------------|-------------------------------------------|
|        |                                          |               |          | Pre  | Post  | p value | R     | p value | R     | p value |
| OTU_6  | Bifidobacterium longum strain HB1A55049  | MH685165.1    | 99%      | 2.19±2.28 | 1.23±1.03 | 0.01 | -0.24 | 0.26  | -0.19 | 0.38  |
| OTU_7  | Fusicatenibacter saccharivoros strain ASD2149 | MG564316.1    | 99%      | 3.29±3.05 | 5.38±5.04 | 0.04 | 0.26  | 0.22  | -0.03 | 0.90  |
| OTU_8  | Blautia wexlerae strain AUH-JLD17        | KF374936.1    | 99%      | 4.14±0.15 | 5.40±0.23 | 0.03 | 0.47  | 0.02* | -0.25 | 0.25  |
| OTU_9  | Bacteroides sp. W20                      | LC033792.1    | 99%      | 1.33±2.94 | 0.67±1.48 | <0.01 | 0.06  | 0.78  | -0.23 | 0.28  |
| OTU_10 | Phascolarctobacterium faecium strain SN20 | L998073.1     | 99%      | 0.42±0.86 | 0.31±0.76 | 0.04 | -0.26 | 0.21  | 0.22  | 0.30  |
| OTU_11 | Streptococcus salivarius strain NCTC7366 | LS483366.1    | 99%      | 0.86±0.62 | 0.41±0.53 | 0.01 | -0.33 | 0.11  | 0.51  | 0.01* |
| OTU_12 | Acidaminococcus intestini strain DN00404 | KU726655.1    | 99%      | 0.15±0.44 | 0.17±0.50 | 0.047 | -0.03 | 0.89  | -0.38 | 0.06  |
| OTU_13 | Alistipes putredinis strain Marseille-P1137 | LT223618.1    | 99%      | 0.33±0.56 | 0.15±0.34 | 0.02 | -0.29 | 0.17  | 0.41  | 0.05* |
| OTU_14 | Oscillibacter sp. PE192                  | AP018532.1    | 99%      | 0.22±0.19 | 0.13±0.15 | 0.02 | -0.07 | 0.75  | -0.11 | 0.62  |
| OTU_15 | Alistipes onderdonkii partial strain Marseille-P591 | LT558807.1    | 98%      | 0.19±0.34 | 0.03±0.05 | 0.03 | -0.13 | 0.54  | 0.35  | 0.09  |
| OTU_16 | Bacteroides ovatus strain V975          | LT622246.1    | 98%      | 2.56±3.23 | 1.53±1.92 | 0.03 | -0.06 | 0.80  | 0.49  | 0.01* |
| OTU_17 | [Clostridium] leptum strain DSM 753      | NR_114789.1   | 95%      | 0.11±0.09 | 0.05±0.05 | 0.01 | -0.48 | 0.02* | -0.05 | 0.82  |
| OTU_18 | [Clostridium] innocuum strain I46        | CP022722.1    | 99%      | 0.15±0.13 | 0.10±0.16 | 0.04 | -0.18 | 0.40  | 0.08  | 0.71  |
| OTU_19 | Odoribacter splanchnicus strain Marseille-P862 | LT558826.1    | 99%      | 0.15±0.23 | 0.05±0.08 | 0.02 | 0.09  | 0.67  | 0.03  | 0.88  |
| OTU_20 | Anaeromassilibacillus sp. Marseille-P3371 | LT725669.1    | 99%      | 0.03±0.06 | 0.01±0.02 | 0.02 | -0.25 | 0.23  | -0.09 | 0.69  |
| OTU_21 | Clostridium sp. 619                      | AB739698.1    | 98%      | 0.10±0.15 | 0.07±0.13 | <0.01 | -0.11 | 0.62  | -0.06 | 0.77  |
| OTU_22 | [Clostridium] indolis strain BN-15       | MF14975.1     | 99%      | 0.08±0.10 | 0.03±0.03 | 0.01 | -0.24 | 0.26  | 0.45  | 0.03* |
| OTU_23 | Eubacterium sp. Marseille-P2543          | LT598590.1    | 97%      | 0.01±0.01 | <0.01    | 0.03 | -0.48 | 0.02* | 0.39  | 0.06  |
| OTU_24 | Gemella sanguinis strain NTUH_8428       | AB775575.1    | 99%      | 0.01±0.01 | <0.01    | 0.03 | -0.34 | 0.11  | 0.06  | 0.78  |

The Spearman’s correlation coefficient (R) and p value with significant correlation are indicated in bold letters and asterisk (*).
after supplementation with PHGG (Table 1). The frequency of defecation in all 13 ASD children was less than 3 times per week prior to supplementation with PHGG and thus, the disorder was categorized as constipation as per the general definition. However, the frequency of defecation increased to more than 3 times per week in nine of the 13 ASD children after PHGG supplementation. In the remaining four children, the frequency of defecation was twice per week following PHGG supplementation, but since the original defecation frequency prior to PHGG supplementation was once per week in all four, it was considered that constipation symptoms improved moderately.

Our results showed that the gut microbiota was altered by PHGG supplementation. For instance, for alpha-diversity indices, both richness and evenness significantly decreased. In addition, PHGG supplementation changed the relative abundance of nine bacterial genera and 19 OTUs. It is possible that the aforementioned alteration of the gut microbiota contributed to improvement of constipation symptoms in ASD children. In past studies, alteration of the gut microbiota with supplementation with prebiotics or probiotics occurred simultaneously with improvement of constipation symptoms, but it was unclear what event preceded the other. Nonetheless, in a separate work, it was suggested that fecal microbiota transplantation, that is, artificial alteration of the gut microbiota, improved constipation symptoms. Moreover, in the present study, the abundance of OTU_9, OTU_75, OTU_146, which were significantly affected by PHGG supplementation, showed a significant correlation with the frequency of defecation (Table 2 and Fig. 5). Thus, both the existing evidence and our results seem to indicate that improvement of constipation symptoms is preceded by a beneficial alteration of the gut microbiota.

It is known that constipation and gut dysbiosis lead to an increase in mucosal permeability (leaky-gut) which may be also the case for ASD. Indeed, de Magistris et al. reported an increase in mucosal permeability in ASD children, and Emanuele et al. demonstrated an increased concentration of serum endotoxin in patients with severe ASD. Due to an increase in mucosal permeability, PBMCs in ASD children are likely to be more exposed to endotoxins than those in TD children, which causes PBMCs to be highly sensitized to endotoxin stimulation, as reported by Jyonouchi et al. In addition, Jyonouchi et al. detected that, as a response to endotoxins (lipopolysaccharides), PBMCs in children with ASD produced significantly higher amounts of IL-1beta, IL-6 and TNF-alpha than did those in TD children. It is worth noting that in the present work, PHGG supplementation affected the same inflammatory cytokines. Indeed, it was found that in serum IL-1beta significantly decreased and IL-6 and TNF-alpha tended to decrease. Taken together, it can be inferred that, by improving gut dysbiosis and leaky-gut symptoms, PHGG supplementation helped decrease the load of endotoxins from the intestine, which in turn resulted in a decreased production of serum inflammatory cytokines.

Brain inflammation is one causal factor for ASD and is believed...
to derive as a consequence of systemic inflammation and/or neuroinflammation of the central nervous system.\textsuperscript{27,38} Considering the brain-gut axis, systemic inflammation can be caused by a leaky gut and an elevated load of endotoxins, and neuroinflammation by inflammation of the enteric nervous system and the hypothalamic-pituitary-adrenal axis.\textsuperscript{2} Since PHGG supplementation was found to help attenuate systemic inflammation, it seems that PHGG supplementation, perhaps via improvement of the leaky gut, halts further progression of systemic inflammation. The obtained ABC-J irritability subscales seem to agree with these results, as behavioral symptoms of ASD significantly ameliorated after PHGG supplementation was initiated. However, the frequency of defecation and ABC-J irritability subscales correlated differentially with the abundance of OTUs. For example, the frequency of defecation correlated with three OTUs and irritability subscales with four different OTUs. Therefore, this apparent discrepancy may imply that alteration of the gut microbiota by PHGG supplementation affected behavioral symptoms not only by improving constipation and leaky-gut symptoms, but also possibly by blocking neuroinflammation of the central nervous system.

Changes in the abundance of genus \textit{Blautia} and OTU_9, which showed a high homology to \textit{Blautia wexlerae} is of high interest. In our previous study, which was conducted in the same geographic regions,\textsuperscript{19} the abundance of genus \textit{Blautia} was significantly lower in children with ASD than it was in TD children. Due to OTU_9 showed a positive correlation with the frequency of defecation, the decrease in \textit{Blautia} genus detected in ASD children may be associated with constipation, which seems to provide evidence of the presence of gut dysbiosis, at least in Japanese ASD children. With respect to \textit{Faecalibacterium}, in our previous study\textsuperscript{19} its abundance was higher in the gut microbiota of ASD children than in that of TD children, but in the present work it was unaffected by PHGG supplementation. However, in the present work the abundance of OTU_18, which showed a high homology to \textit{Faecalibacterium prausnitzii}, had a strong positive correlation with the ABC-J irritability subscales ($p<0.05$; Supplemental Fig. 1$^*$). Therefore, based on these results, it is recommended that further research on the relationship of \textit{Faecalibacterium} with ASD is conducted.

In summary, in the present work it was shown that PHGG supplementation to diets of constipated ASD children helped improve gut dysbiosis and constipation symptoms, which in turn helped attenuate the level of serum inflammation cytokines and

\*See online. https://doi.org/10.3164/jcbn.18-105

\*See online. https://doi.org/10.3164/jcbn.18-105

\*See online. https://doi.org/10.3164/jcbn.18-105
behavioral irritability. Although the decreasing rate of the ABC-J irritability subscales may seem to be lower than that usually achieved by typical antipsychotics such as aripiprazole, but it should be stressed that this decrease was achieved not by medication, but merely by supplementation of prebiotics with no food intervention. Finally, in the present study, although the number of samples from ASD children may be considered relatively small, our results indicate that PHGG supplementation to diets may be a good therapeutic approach for treating ASD symptoms. A future clinical study using a larger number of samples is highly recommended as it shall provide more solid evidence and confirm our findings.

Author Contributions

RI, YS, MO, TT and YN designed research, ZY and MO prepared PHGG, YS, SU, CS and KN enrolled the patients and collected fecal and serum samples, RI, YS, YK and RT conducted the experiments, RI, TT and YN wrote the manuscript. All authors have read and approved the final manuscript.

Acknowledgments

The authors would like to thank Prof. Hiroshi Hara of Hokkaido University and Prof. Tatsuya Morita and Prof. Naomichi Nishimura of Shizuoka University for their helpful advice regarding dietary fiber.

Conflict of Interest

ZY and MO are employed by Taiyo Kagaku Corporation that sells PHGG commercially and partly funded the research budget. Other authors have no conflict of interest.

References

1 Hughes HK, Rose D, Ashwood P. The gut microbiota and dysbiosis in autism spectrum disorders. Curr Neurol Neurosci Rep 2018; 18: 81.
2 Li Q, Han Y, Dy ABC, Hagerman RJ. The gut microbiota and autism spectrum disorders. Front Cell Neurosci 2017; 11: 120.
3 Inoue R, Sakae Y, Sawai C, et al. A preliminary investigation on the relationship between gut microbiota and gene expressions in peripheral mononuclear cells of infants with autism spectrum disorders. Biosci Biotechnol Biochem 2016; 80: 2450–2458.
4 Zhu L, Liu W, Alkhouri R, et al. Microbiome alterations in the short-term VSL#3 probiotic treatment in patients with functional constipation. J Clin Gastroenterol Nutr 2018; 64: 106–111.
5 Khalif IL, Quigley EM, Konovitch EA, Maximova ID. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 2005; 37: 838–849.
6 Ibrahim SH, Voigt RG, Katsic SK, Weaver AL, Barbaresi WJ. Incidence of gastrointestinal symptoms in children with autism: a population-based study. Pediatrics 2009; 124: 680–686.
7 Ohashi Y, Sumitani K, Tokunaga M, Ishihara N, Okubo T, Fujisawa T. Consumption of partially hydrolysed guar gum stimulates Bifidobacteria and butyrate-producing bacteria in the human large intestine. Benef Microbes 2015; 6: 451–455.
8 Okubo T, Ishihara N, Takashahi H, et al. Effects of partially hydrolyzed guar gum intake on human intestinal microflora and its metabolism. Biosci Biotechnol Biochem 1994; 58: 1364–1369.
9 Grimaldi R, Gibson GR, Vulevic J, et al. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbience 2018; 6: 133.
10 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.), Arlington: American Psychiatric Publishing, 2013.
11 Kamio Y, Yukihiro R, Adachi J, et al. Reliability and validity of the pervasive developmental disorder (PDD)-Autism Society Japan Rating Scale (PARS): a behavior checklist for adolescents and adults with PDDs. Clin Psychiatry (Seishin-Igaku) 2006; 48: 495–505.
12 Robins DL, Fein D, Barton ML, Green JA. The Modified Checklist for Autism in Toddlers: an initial study investigating the early detection of autism and pervasive developmental disorders. J Autism Dev Disord 2001; 31: 131–144.
13 Ono Y. Factor validity and reliability for the Aberrant Behavior Checklist-Community in a Japanese population with mental retardation. Res Dev Disabil 1996; 17: 303–309.
14 Kawada Y, Naito Y, Andoh A, Ozeki M, Inoue R. Effect of storage and DNA extraction method on 16S rRNA-profiled fecal microbiota in Japanese adults. J Clin Biochem Nutr 2018; 64: 106–111.
15 Inoue R, Oue-Hikano R, Tsukahara T, et al. Prediction of functional profiles of gut microbiota from 16S rRNA metagenomic data provides a more robust evaluation of gut dysbiosis occurring in Japanese type 2 diabetic patients. J Clin Biochem Nutr 2017; 61: 217–221.
16 Kramps K, Booth T, Chapman B, et al. Cloud BioLinux: pre-configured and on-demand bioinformatics computing for the genomics community. BMC Bioinformatics 2012; 13: 42.
17 McMurrie PJ, Holmes S. Phylseqoe: a bioconductor package for handling and analysis of high-throughput phylogenetic sequence data. Pac Symp Biocomput 2012: 235–246.
18 Idring S, Lundberg M, Sturm H, et al. Changes in prevalence of autism spectrum disorders in 2001–2011: findings from the Stockholm youth cohort. J Autism Dev Disord 2015; 45: 1766–1773.
19 Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750–759.
20 Kim SE, Choi SC, Park KS, et al. Change of fecal flora and effectiveness of the short-term VSL#3 probiotic treatment in patients with functional constipation. J Neurogastroenterol Motil 2015; 21: 111–120.
21 Kleessen B, Sykura B, Zanft HJ, Blaas M. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr 1997; 65: 1397–1402.
22 Ishizuka A, Tomizuka K, Aoki R, et al. Effects of administration of Bifidobacterium animalis subsp. lactis GCL2505 on defecation frequency and bifidobacterial microbiota composition in humans. J Biosci Bioeng 2012; 113: 587–591.
23 Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004; 38: 475–483.
24 de Magistris L, Familiari V, Pascotto A, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010; 51: 418–424.
25 Emanuele E, Orsi P, Boso M, et al. Low-grade endotoxemia in patients with severe autism. Neurosci Lett 2010; 471: 162–165.
26 Jonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001; 120: 170–179.
27 Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005; 46: 1724–1743.
28 Angelidou A, Asadi S, Aylsandratos KD, Karagkouni A, Kourembanas S, Theoharides TC. Perinatal stress, brain inflammation and risk of autism-review and proposal. BMC Pediatrics 2012; 12: 89.